454 related articles for article (PubMed ID: 25752454)
1. mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia.
Nguyen LH; Brewster AL; Clark ME; Regnier-Golanov A; Sunnen CN; Patil VV; D'Arcangelo G; Anderson AE
Epilepsia; 2015 Apr; 56(4):636-46. PubMed ID: 25752454
[TBL] [Abstract][Full Text] [Related]
2. mTOR-dependent alterations of Kv1.1 subunit expression in the neuronal subset-specific Pten knockout mouse model of cortical dysplasia with epilepsy.
Nguyen LH; Anderson AE
Sci Rep; 2018 Feb; 8(1):3568. PubMed ID: 29476105
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the mammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice.
Sunnen CN; Brewster AL; Lugo JN; Vanegas F; Turcios E; Mukhi S; Parghi D; D'Arcangelo G; Anderson AE
Epilepsia; 2011 Nov; 52(11):2065-75. PubMed ID: 21973019
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin improves social and stereotypic behavior abnormalities induced by pre-mitotic neuronal subset specific Pten deletion.
Narvaiz DA; Nolan SO; Smith GD; Holley AJ; Reynolds CD; Blandin KJ; Nguyen PH; Tran DLK; Lugo JN
Genes Brain Behav; 2023 Aug; 22(4):e12854. PubMed ID: 37376966
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development.
Jeong A; Wong M
J Child Neurol; 2018 Jan; 33(1):55-63. PubMed ID: 29246093
[TBL] [Abstract][Full Text] [Related]
6. mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia.
Nguyen LH; Mahadeo T; Bordey A
J Neurosci; 2019 Apr; 39(14):2762-2773. PubMed ID: 30700531
[TBL] [Abstract][Full Text] [Related]
7. Commentary: mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia.
Wong M
Epilepsia; 2016 Sep; 57(9):1349-50. PubMed ID: 27522175
[No Abstract] [Full Text] [Related]
8. Hyperactive mTOR signals in the proopiomelanocortin-expressing hippocampal neurons cause age-dependent epilepsy and premature death in mice.
Matsushita Y; Sakai Y; Shimmura M; Shigeto H; Nishio M; Akamine S; Sanefuji M; Ishizaki Y; Torisu H; Nakabeppu Y; Suzuki A; Takada H; Hara T
Sci Rep; 2016 Mar; 6():22991. PubMed ID: 26961412
[TBL] [Abstract][Full Text] [Related]
9. Molecular interplay between hyperactive mammalian target of rapamycin signaling and Alzheimer's disease neuropathology in the NS-Pten knockout mouse model.
Hodges SL; Reynolds CD; Smith GD; Jefferson TS; Nolan SO; Lugo JN
Neuroreport; 2018 Sep; 29(13):1109-1113. PubMed ID: 29965873
[TBL] [Abstract][Full Text] [Related]
10. mTORC2 Inhibition Improves Morphological Effects of PTEN Loss, But Does Not Correct Synaptic Dysfunction or Prevent Seizures.
Cullen ER; Tariq K; Shore AN; Luikart BW; Weston MC
J Neurosci; 2023 Feb; 43(5):827-845. PubMed ID: 36526374
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia.
Ljungberg MC; Sunnen CN; Lugo JN; Anderson AE; D'Arcangelo G
Dis Model Mech; 2009; 2(7-8):389-98. PubMed ID: 19470613
[TBL] [Abstract][Full Text] [Related]
12. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis.
Citraro R; Leo A; Constanti A; Russo E; De Sarro G
Pharmacol Res; 2016 May; 107():333-343. PubMed ID: 27049136
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mammalian target of rapamycin with rapamycin reverses hypertrophic cardiomyopathy in mice with cardiomyocyte-specific knockout of PTEN.
Xu X; Roe ND; Weiser-Evans MC; Ren J
Hypertension; 2014 Apr; 63(4):729-39. PubMed ID: 24446058
[TBL] [Abstract][Full Text] [Related]
14. Impact of mTOR hyperactive neurons on the morphology and physiology of adjacent neurons: Do PTEN KO cells make bad neighbors?
LaSarge CL; Pun RYK; Gu Z; Santos VR; Danzer SC
Exp Neurol; 2019 Nov; 321():113029. PubMed ID: 31377403
[TBL] [Abstract][Full Text] [Related]
15. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex.
Rensing N; Han L; Wong M
Epilepsia; 2015 Jul; 56(7):1088-97. PubMed ID: 26122303
[TBL] [Abstract][Full Text] [Related]
16. Hypervascularization in mTOR-dependent focal and global cortical malformations displays differential rapamycin sensitivity.
Zhang L; Huang T; Teaw S; Bordey A
Epilepsia; 2019 Jun; 60(6):1255-1265. PubMed ID: 31125447
[TBL] [Abstract][Full Text] [Related]
17. Four-week rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy.
Foltz SJ; Luan J; Call JA; Patel A; Peissig KB; Fortunato MJ; Beedle AM
Skelet Muscle; 2016; 6():20. PubMed ID: 27257474
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin prevents, but does not reverse, aberrant migration in Pten knockout neurons.
Getz SA; DeSpenza T; Li M; Luikart BW
Neurobiol Dis; 2016 Sep; 93():12-20. PubMed ID: 26992888
[TBL] [Abstract][Full Text] [Related]
19. mTOR: A pathogenic signaling pathway in developmental brain malformations.
Crino PB
Trends Mol Med; 2011 Dec; 17(12):734-42. PubMed ID: 21890410
[TBL] [Abstract][Full Text] [Related]
20. A mouse model of DEPDC5-related epilepsy: Neuronal loss of Depdc5 causes dysplastic and ectopic neurons, increased mTOR signaling, and seizure susceptibility.
Yuskaitis CJ; Jones BM; Wolfson RL; Super CE; Dhamne SC; Rotenberg A; Sabatini DM; Sahin M; Poduri A
Neurobiol Dis; 2018 Mar; 111():91-101. PubMed ID: 29274432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
